Phase II Study for Efficacy and Safety of nab-paclitaxel for Previously Treated Advanced Non-small Cell Lung Cancer
Not Applicable
- Conditions
- lung cancer
- Registration Number
- JPRN-UMIN000010737
- Lead Sponsor
- Tokyo Metropolitan Cancer and Infection diseases Center Komagome Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
1) Previously treated with paclitaxel 2) With uncontrolled brain metastasis 3) With clinically active infection 4) With severe complication (cardiac diseases, interstitial pneumonia, uncontrolled hypertension or diabetes) 5) With uncontrolled pleural effusion 6) With active other organ cancer 7) With the history of severe drug allergy 8) With the history of hypersensivity for paclitaxel, albumin-containing agents 9) With uncontrolled digestive ulcer 10) Any patients judged by the investigator to be unfit to participate in the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method progression-free survival, overall survival, toxicities, number of cycles